A Phase 1 interventional study of Tirzepatide and Single Dose Pen in Healthy, sponsored by Eli Lilly and Company. Completed at 3 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-15.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to look at the amount of the study drug, tirzepatide, that gets into the blood stream and how long it takes the body to get rid of it when given using two different devices. The study will also evaluate the safety and tolerability of tirzepatide and information about any side effects experienced will be collected. For each participant, the total duration of the study will be approximately 14 weeks, including screening.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single dose of 5 milligrams (mg) tirzepatide administered subcutaneously (SC) via an SDP in Period 1 followed by a single dose of 5 mg tirzepatide administered SC via a MUPFP in Period 2. There was a washout period of at least 35 days between tirzepatide dose administrations.
Drug: Tirzepatide · Device: Single Dose Pen · Device: Multi-use Prefilled Pen
Participants received a single dose of 5 mg tirzepatide administered SC via a MUPFP in Period 1 followed by a single dose of 5 mg tirzepatide administered SC via an SDP in Period 2. There was a washout period of at least 35 days between tirzepatide dose administrations.
Drug: Tirzepatide · Device: Single Dose Pen · Device: Multi-use Prefilled Pen
Administered SC
Also known as: LY3298176
Used to administer tirzepatide SC
Used to administer tirzepatide SC
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Tirzepatide
PK: Cmax of Tirzepatide
Time frame: Predose, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 336, and 480 hours post Day 1 dose and on Day 36 of each study period.
PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Time t, Where t is the Last Time Point With a Measurable Concentration (AUC[0-t]) of Tirzepatide
PK: AUC(0-t) of Tirzepatide
Time frame: Predose, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 336, and 480 hours post Day 1 dose and on Day 36 of each study period.
PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Tirzepatide
PK: AUC(0-∞) of Tirzepatide
Time frame: Predose, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 336, and 480 hours post Day 1 dose and on Day 36 of each study period.
| Milestone | Sequence 1: Tirzepatide by SDP / MUPFP | Sequence 2: Tirzepatide by MUPFP / SDP |
|---|---|---|
| Started | 34 | 31 |
| Received at least 1 dose of study drug | 34 | 31 |
| Completed | 31 | 31 |
| Not completed | 3 | 0 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Physician decision | 1 | 0 |
| Milestone | Sequence 1: Tirzepatide by SDP / MUPFP | Sequence 2: Tirzepatide by MUPFP / SDP |
|---|---|---|
| Started | 31 | 31 |
| Received at least 1 dose of study drug | 31 | 31 |
| Completed | 31 | 31 |
| Not completed | 0 | 0 |
PK: Cmax of Tirzepatide
| nanograms per milliliter (ng/mL) | Tirzepatide (SDP) | Tirzepatide (MUPFP) |
|---|---|---|
| Pharmacokinetics (PK): Maximum Concentration (Cmax) of Tirzepatide | 647 ± 31 | 524 ± 27 |
PK: AUC(0-t) of Tirzepatide
| nanogram *hour per milliliter (ng*h/mL) | Tirzepatide (SDP) | Tirzepatide (MUPFP) |
|---|---|---|
| PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Time t, Where t is the Last Time Point With a Measurable Concentration (AUC[0-t]) of Tirzepatide | 124000 ± 23 | 118000 ± 22 |
PK: AUC(0-∞) of Tirzepatide
| ng*h/mL | Tirzepatide (SDP) | Tirzepatide (MUPFP) |
|---|---|---|
| PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Tirzepatide | 126000 ± 22 | 119000 ± 22 |
Collected over Baseline Up To 82 Days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tirzepatide (SDP) | 0/65 (0%) | 0/65 (0%) | 38/65 (58.5%) |
| Tirzepatide (MUPFP) | 0/62 (0%) | 0/62 (0%) | 28/62 (45.2%) |
| Event | Tirzepatide (SDP) | Tirzepatide (MUPFP) |
|---|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 17/65 | 14/62 |
| NauseaGastrointestinal disorders | 16/65 | 14/62 |
| DyspepsiaGastrointestinal disorders | 10/65 | 7/62 |
| HeadacheNervous system disorders | 10/65 | 5/62 |
| VomitingGastrointestinal disorders | 9/65 | 7/62 |
| PainGeneral disorders | 4/65 | 6/62 |
| DiarrhoeaGastrointestinal disorders | 3/65 | 4/62 |
All randomized participants.
| Age, Continuous(years) | Sequence 1: Tirzepatide by SDP / MUPFP | Sequence 2: Tirzepatide by MUPFP / SDP | Total |
|---|---|---|---|
| Mean | 41.10 ± 13.32 | 41.10 ± 14.52 | 41.10 ± 13.79 |
| Sex: Female, Male(Participants) | Sequence 1: Tirzepatide by SDP / MUPFP | Sequence 2: Tirzepatide by MUPFP / SDP | Total |
|---|---|---|---|
| Female | 18 | 17 | 35 |
| Male | 16 | 14 | 30 |
| Ethnicity (NIH/OMB)(Participants) | Sequence 1: Tirzepatide by SDP / MUPFP | Sequence 2: Tirzepatide by MUPFP / SDP | Total |
|---|---|---|---|
| Hispanic or Latino | 16 | 17 | 33 |
| Not Hispanic or Latino | 18 | 14 | 32 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Sequence 1: Tirzepatide by SDP / MUPFP | Sequence 2: Tirzepatide by MUPFP / SDP | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 2 | 6 |
| White | 29 | 29 | 58 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Sequence 1: Tirzepatide by SDP / MUPFP | Sequence 2: Tirzepatide by MUPFP / SDP | Total |
|---|---|---|---|
| United States | 34 | 31 | 65 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2023 to primary completion in Jul 2023, 3 months.
Results were first posted in Oct 2024, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide